Jan 05, 2021
Revitope Oncology Announces Strategic Collaboration with Janssen to Leverage its Unique T Cell Engager Platform
Dec 02, 2020
Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration
Jun 01, 2020
Despite Increased Competition from the Recent Launch of Janssen's Stelara, Takeda's Entyvio Continues to Shine as a Leading Ulcerative Colitis Treatment
May 01, 2020
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
Apr 28, 2020
Philogen Announces Option Exercise by Janssen
Mar 23, 2020
Global Hidradenitis Suppurativa (HS) Industry Assessment, 2020 Featuring InflaRx, Novartis Pharma, Incyte Corp, UCB Biopharma, and Janssen Pharma
Jan 06, 2020
Dr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of Science
Dec 30, 2019
Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
Dec 07, 2019
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
Nov 08, 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Jun 02, 2019
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
Feb 28, 2019
Dr. Guislain Museum and Janssen Seek Global Nominations for Annual "Breaking the Chains of Stigma" Award
Oct 29, 2018
New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans
Oct 25, 2018
AMPEL's System For Drug Repositioning Confirmed By Success Of Phase 2 Trial Of Stelara In Lupus
Sep 27, 2018
Janssen Elects Not to Continue Agreement with Geron for Imetelstat
Sep 10, 2018
Janssen Recognizes World Suicide Prevention Day with New Video Series
Aug 27, 2018
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström's Macroglobulinemia, a Rare Blood Cancer
Jun 11, 2018
Janssen to Showcase New Data Across Broad Rheumatology Portfolio and Immunology Pipeline at EULAR 2018
Jun 04, 2018
James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research
Mar 08, 2018
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management